Skip to main content
SAMSUNG BIOLOGICS CO.,LTD. logo

SAMSUNG BIOLOGICS CO.,LTD. — Investor Relations & Filings

Ticker · 207940 ISIN · KR7207940008 KO Manufacturing
Open in API
Filings indexed 765 across all filing types
Latest filing 2026-05-20 Director's Dealing
Country KR South Korea
Listing KO 207940

About SAMSUNG BIOLOGICS CO.,LTD.

https://samsungbiologics.com/

Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) that provides end-to-end services to the biopharmaceutical industry. The company offers a comprehensive suite of solutions covering the entire product lifecycle, from early-stage cell line and process development to large-scale commercial manufacturing of drug substances. Key services include analytical development, quality and biosafety testing, and aseptic fill/finish of drug products. Samsung Biologics also supports the development and manufacturing of new modalities, including antibody-drug conjugates (ADCs) and mRNA. Leveraging its large-scale, CGMP-compliant facilities, the company serves a global client base of pharmaceutical companies with tailored and flexible manufacturing solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 91% confidence The document is a ‘임원ㆍ주요주주 특정증권등 소유상황보고서’ which details personal share holdings and a recent transaction by an executive (조성환). This matches the definition of a Director’s Dealing report (insider share transactions by company directors/executives).
2026-05-20 Korean
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 84% confidence The document is titled “사업보고서” (Business Report) for the fiscal year 2025 (2025.01.01–2025.12.31) filed with the Financial Services Commission and Korea Exchange. It contains the full company overview, governance details, historical activities, and will include financial statements, not just an announcement. Its length (~495k characters) indicates this is the complete annual report, not a mere publication notice or correction notice. Therefore it corresponds to an Annual Report (10-K). FY 2025
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제16기)” and covers the period January 1 to March 31, 2026, with detailed financial statements, segment results, production data, risk management policies, and notes typical of a full quarterly report. It contains substantive financial data rather than just an announcement or summary. Under the taxonomy, this corresponds to an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is titled '최대주주등소유주식변동신고서' which translates to 'Major Shareholding Change Report'. It details changes in the ownership of shares by major shareholders, including specific dates, share counts, and transactions such as purchases and sales. The document includes detailed tables of shareholding changes by individual shareholders and entities. There is no indication of financial statements, earnings data, management discussion, or other report types. The content clearly matches the definition of a 'Major Shareholding Notification' which reports changes in significant share ownership levels. The document length is 4074 characters, which is sufficient for a detailed notification but not a full financial report. Therefore, the appropriate classification is 'MRQ' for Major Shareholding Notification.
2026-05-04 Korean
동일인등출자계열회사와의상품ㆍ용역거래변경
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory announcement detailing changes in goods and services transactions between Samsung Biologics and its affiliated companies under the Fair Trade Act. It does not represent an annual or interim financial report, earnings release, AGM materials, or any other specific category like M&A or dividends. It is a routine compliance disclosure of related‐party transactions, which falls under miscellaneous regulatory filings. Therefore, it is classified as a general Regulatory Filing (RNS).
2026-04-24 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 92% confidence The document is a public disclosure of consolidated provisional operating results for Q1 2026, providing headline figures for revenue, operating profit, pre-tax income, and net profit compared to prior periods. It is clearly an initial summary of quarterly financial performance (잠정실적), not a full interim report or annual filing. This matches the definition of an Earnings Release. Q1 2026
2026-04-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.